Bollu V - Search Results

1

A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL).

Salles G, Schuster SJ, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith S, Jiménez-Ubieto A, Davis KL, Nagar S, Zhang J, Bollu V, Jousseaume E, Ramos R, Wang Y, Link BK. Salles G, et al. Among authors: bollu v. Hemasphere. 2022 Jun 21;6(7):e745. doi: 10.1097/HS9.0000000000000745. eCollection 2022 Jul. Hemasphere. 2022. PMID: 35813099 Free PMC article.

2

Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.

Qi CZ, Bollu V, Yang H, Dalal A, Zhang S, Zhang J. Qi CZ, et al. Among authors: bollu v. Clin Ther. 2021 Aug;43(8):1300-1319.e8. doi: 10.1016/j.clinthera.2021.06.011. Epub 2021 Aug 8. Clin Ther. 2021. PMID: 34380609

3

Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.

Schuster SJ, Zhang J, Yang H, Agarwal A, Tang W, Martinez-Prieto M, Bollu V, Kuzan D, Maziarz RT, Kersten MJ. Schuster SJ, et al. Among authors: bollu v. Leuk Lymphoma. 2022 Apr;63(4):845-854. doi: 10.1080/10428194.2021.2010069. Epub 2022 Jan 2. Leuk Lymphoma. 2022. PMID: 34978255

4

Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy - a retrospective cohort study using CMS 100% Medicare claims database.

Yang H, Bollu V, Lim S, Tesfaye M, Dalal AA, Lax A, Sethi S, Zhao J. Yang H, et al. Among authors: bollu v. Leuk Lymphoma. 2023 Feb;64(2):339-348. doi: 10.1080/10428194.2022.2147395. Epub 2022 Nov 21. Leuk Lymphoma. 2023. PMID: 36408973

5

Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.

Maziarz RT, Yang H, Liu Q, Wang T, Zhao J, Lim S, Lee S, Dalal A, Bollu V. Maziarz RT, et al. Among authors: bollu v. Leuk Lymphoma. 2022 Sep;63(9):2052-2062. doi: 10.1080/10428194.2022.2060503. Epub 2022 Apr 14. Leuk Lymphoma. 2022. PMID: 35422192

6

The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Guérin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A. Guérin A, et al. J Med Econ. 2013;16(1):125-33. doi: 10.3111/13696998.2012.693896. Epub 2012 Jun 6. J Med Econ. 2013. PMID: 22587385 Free article.

7

Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year.

Donohue JF, Ganapathy V, Bollu V, Stensland MD, Nelson LM. Donohue JF, et al. Among authors: bollu v. Clin Ther. 2017 Jan;39(1):66-74. doi: 10.1016/j.clinthera.2016.11.021. Epub 2016 Dec 20. Clin Ther. 2017. PMID: 28011247 Clinical Trial.

8

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.

Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Wu EQ, et al. Curr Med Res Opin. 2010 Dec;26(12):2861-9. doi: 10.1185/03007995.2010.533648. Epub 2010 Nov 9. Curr Med Res Opin. 2010. PMID: 21062136

9

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.

Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ. Signorovitch JE, et al. Curr Med Res Opin. 2011 Jun;27(6):1263-71. doi: 10.1185/03007995.2011.576238. Epub 2011 Apr 28. Curr Med Res Opin. 2011. PMID: 21524239 Clinical Trial.

10

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.

Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J. Wu EQ, et al. Among authors: bollu v. Curr Med Res Opin. 2010 Jan;26(1):61-9. doi: 10.1185/03007990903396469. Curr Med Res Opin. 2010. PMID: 19905880

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

34 results

Search Page